Sulfonylureas: Do we need to introspect safety again?

Expert Opinion on Drug Safety

Volumn 10, Issue 6, 2011, Pages 851-861

  Sehra, Devindra ^a   Sehra, Sudhish ^a   Sehra, Shiv Tej ^a  

^a Sehra Medical Centre   (India)

Author keywords

Adverse effects; KATP channels; Safety; Sulfonylurea

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GROWTH HORMONE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; GROWTH HORMONE RELEASE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MONOTHERAPY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH PARESIS; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 80054735095     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.583234     Document Type: Review

References (88)

1. Kar P, Holt RI. The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes. Cardiovasc Drugs Ther 2008;22(3):207-13
2. Bell DS. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006;174(2):185-6 (Pubitemid 43166271)
3. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention 2008.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
5. Valensi P, Slama G. Sulphonylureas and cardiovascular risks: facts and controversies. Br J Diabetes Vasc Dis 2006;6(4):159-65 (Pubitemid 44334717)
6. Schwartz TB, Meinert CL. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Perspect Biol Med 2004;47(4):564-74 (Pubitemid 39372366)
7. Rao AD, Kuhadiya N, Reynolds K, et al. Is the combination of sulphonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008;31(8):1672-8
8. Lefer DJ, Nichols CG, Coetzee WA. Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 2009;19(2):61-7
9. Miki T, Liss B, Minami K, et al. ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci 2001;4(5):507-12 (Pubitemid 32397188)
10. Nagashima K, Takahashi A, Ikeda H, et al. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmacological properties and tissue selectivity. Diabetes Res Clin Pract 2004;66(S1):75-8
11. Khalangot M, Tronmcho M, Kravchenko V, et al. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009;86(3):247-53
12. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124(1 Pt 2):136-45 (Pubitemid 26011611)
13. Zeller M, Danchin N, Simon D, et al. for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010;95(11):4993-5002
14. Kilo C, Miller JP, Williamson JR. The crux of the UGDP. Spurious results and biologically inappropriate data analysis. Diabetologia 1980;18(3):179-85
15. Sato T, Nishida H, Miyazaki M, et al. Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev 2006;22(5):341-7 (Pubitemid 44446428)
16. Kilo C, Miller JP, Williamson JR. The Achilles heel of the University Group Diabetes Program. JAMA 1980;243(5):450-7 (Pubitemid 10207640)
17. Holman RR, Paul SK, Bethel MA, et al. 10-year follow up of glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89
18. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998;31(5):950-6 (Pubitemid 28212491)
19. Zarich SW. Potential of glucose-lowering drugs to reduce cardiovascular events. Curr Diab Rep 2009;9(1):87-94
20. Thisted H, Johnsen PS, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006;55(Suppl 1):16S-9S
21. Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metabolism 2000;49(10 Suppl 2):17-20
22. Cacciapuoti F, Spiezia R, Bianchi U, et al. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol 1991;67(9):843-7
23. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007;23:479-84 (Pubitemid 47520905)
24. Huffmyer J, Raphael J. Physiology and pharmacology of myocardial preconditioning and postconditioning. Semin Cardiothorac Vasc Anesth 2009;13(1):5-18
25. Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996;94(9):2297-301 (Pubitemid 26360527)
26. Meier JJ, Gallwitz B, Schmidt WE, et al. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004;90(1):9-12 (Pubitemid 38064530)
27. Huizar JF, Gonzalez LA, Alderman J, et al. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. J Am Coll Cardiol 2003;42(6):1017-21 (Pubitemid 37108586)
28. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174(2):169-74 (Pubitemid 43166269)
29. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33(1):119-24 (Pubitemid 29064081)
30. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314(7093):1512-15 (Pubitemid 27216066)
31. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26(7):650-61 (Pubitemid 40516876)
32. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59
33. Macisaac RJ, Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes (April 2010). Heart Lung Circ 2010;published online Aug 29, 2010, doi:10.1016/j. hlc.2010.07.013
34. Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J 1991;121(4 Pt 2):1274-82
35. Quayle MJ, Nelson T, Standen BN. ATP-Sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997;77:1166-232
36. Sato N, Nakayama T, Asai S, et al. A haplotype in the human Sur2 gene is associated with essential hypertension. J Hum Hypertens 2006;20(1):87-90
37. Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 2003;81(2):133-76 (Pubitemid 36141258)
38. Shi NQ, Ye B, Makielski JC. Function and distribution of the SUR isoforms and splice variants. J Mol Cell Cardiol 2005;39(1):51-60 (Pubitemid 40836044)
39. Yosefy C, Magen E, Kiselevich A, et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004;44(2):215-22 (Pubitemid 38982165)
40. Hasslacher C, Ritz E, Tschope W, et al. Hypertension in Diabetes. Kidney Int Suppl 1988;25:133S-7S
41. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990;39(2):167-74 (Pubitemid 20053276)
42. Boyko EJ, Leonetti DL, Bergstrom RW, et al. Visceral adiposity, fasting plasma insulin, and blood pressure in Japanese-Americans. Diabetes Care 1995;18(2):174-81
43. Asch S, Wingard DL, Barrett-Connor EL. Are insulin and hypertension independently related? Ann Epidemiol 1991;1:231-44
44. Muller DC, Elahi D, Pratley RE, et al. An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 1993;76(3):544-8 (Pubitemid 23086463)
45. Collins VR, Dowse GK, Finch CF, et al. An inconsistent relationship between insulin and blood pressure in three Pacific island populations. J Clin Epidemiol 1990;43(12):1369-78
46. Saad MF, Lillioja S, Nyomba BL, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991;324(11):733-9
47. Zimmet PZ, Collins VR, Dowse GK, et al. Is hyperinsulinaemia a central characteristic of a chronic cardiovascular risk factor clustering syndrome? Mixed findings in Asian Indian, Creole and Chinese Mauritians. Mauritius Noncommunicable Disease Study Group. Diabet Med 1994;11(4):388-96 (Pubitemid 24196065)
48. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-65
49. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 Diabetes (UKPDS 33). Lancet 1998;352(9131):837-53
50. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25(11):2058-64
51. Belcher G, Lambert C, Goh KL, et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract 2004;58(9):833-7 (Pubitemid 39462204)
52. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33(7):1674-85
53. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330(7503):1304-5 (Pubitemid 40813563)
54. Monami M, Lamanna C, Pala L, et al. Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. Exp Clin Endocrinol Diabetes 2008;116(3):184-9 (Pubitemid 351518539)
55. Sliwinska A, Sliwinski T, Kasznicki J, et al. Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells. J Physiol Pharmacol 2010;61(3):347-53
56. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-8 (Pubitemid 44106500)
57. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52(9):1766-77
58. Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009;46(4):279-84
59. Jonasson JM, Ljung R, Talback M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009;52(9):1745-54
60. Currie CJ. The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings. Diabetologia 2009;52(10):2234-5
61. Manderbacka K, Sund R, Koski S, et al. Diabetes and depression? Secular trends in the use of antidepressants among persons with diabetes in Finland in 1997-2007. Pharmacoepidemiol Drug Saf 2011;20(4):338-43
62. Pawaskar MD, Anderson RT, Balkrishnan R. Self-reported predictors of depressive symptomatology in an elderly population with type 2 diabetes mellitus: a prospective cohort study. Health Qual Life Outcomes 2007;5:50
63. Fallon JH, Loughlin SE. Substantia Nigra. In: Paxinos G, editor, The rat nervous system. Volume 1 Academic Press; San Diego: 1985. p 353-74
64. Koua J, Klorig CD, Bloomquist RJ. Potentiating effect of the ATP-sensitive potassium channel blocker glibenclamide on complex I inhibitor neurotoxicity in vitro and in vivo. Neurotoxicology 2006;27(5):826-34
65. Abraira C, Henderson WG, Colwell JA, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998;21(4):574-9 (Pubitemid 28172937)
66. Bernardi H, De Weille JR, Epelbaum J, et al. ATP-modulated K+ channels sensitive to antidiabetic Sulfonylureas are present in adenohypophysis and are involved in growth hormone release. Proc Natl Acad Sci USA 1993;90(4):1340-4 (Pubitemid 23058167)
67. De Weille JR, Fosset M, Epelbaum J, et al. Effectors of ATP-sensitive K+ channels inhibit the regulatory Effects of somatostatin and GH-releasing factor on growth hormone secretion. Biochem Biophys Res Commun 1992;187(2):1007-14
68. ter Braak EW, Appelman AM, van der Tweel I, et al. The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycaemia. Diabetes Care. 2002; 25(1), 107-12
69. Shibasaki T, Hotta M, Masuda A, et al. Plasma GH responses to GHRH and insulin-induced hypoglycaemia in man. J Clin Endocrinol Metab 1985;60(6):1265-7 (Pubitemid 15064794)
70. Masuda A, Shibasaki T, Hotta M, et al. Insulin-induced hypoglycaemia, L-dopa and arginine stimulate GH secretion through different mechanisms in man. Regul Pept 1990;31(1):53-64 (Pubitemid 20354177)
71. Bokvist K, Olsen HL, Høy M, et al. Characterisation of sulphonylurea and ATP-regulated K+ channels in rat pancreatic A-cells. Pflugers Arch 1999;438(4):428-36 (Pubitemid 29419895)
72. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128(3):165-75
73. Martin S, Kolb H, Beuth J, et al. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003;46(12):1611-17 (Pubitemid 38005323)
74. Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83(5):1515-22 (Pubitemid 28501013)
75. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily Gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34(8):535-42 (Pubitemid 39120222)
76. de Boer H, Jansen M, Koerts J, et al. Prevention of weight gain in type 2 diabetes requiring insulin treatment. Diabetes Obes Metab 2004;6(2):114-19 (Pubitemid 38220103)
77. de Boer H, Keizers R, Jansen M, et al. Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen. Diabetes Obes Metab 2006;8(5):517-23 (Pubitemid 44184245)
78. Robb GH, Lowe SM. Lack of weight gain with gliclazide treatment for 30 months in type II diabetes. Curr Med Res Opin 1984;9(1):7-9 (Pubitemid 14134579)
79. Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metab 1994;20(4):394-400
80. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17(10):1100-9 (Pubitemid 24307443)
81. Marbury T, Huang WC, Strange P, et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43(3):155-66 (Pubitemid 29202125)
82. Jain R, Osei K, Kupfer S, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy 2006;26(10):1388-95 (Pubitemid 44521723)
83. Lewitt MS, Yu VK, Rennie GC, et al. Effects of combined insulin-sulfonylurea therapy in type II patients. Diabetes Care 1989;12(6):379-83 (Pubitemid 19140656)
84. United Kingdom Prospective Diabetes Study (UKPDS). 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310(6972):83-8
85. Moses AM, Numann P, Miller M. Mechanism of chlorpropamide-induced antidiuretics in man. Evidence for release of ADH and enhancement of peripheral action. Metabolism 1973;22:59-66
86. Zini S, Ben-Ari Y, Ashford ML. Characterization of sulfonylurea receptors and the action of potassium channel openers on cholinergic neurotransmission in guinea pig isolated small intestine. J Pharmacol Exp Ther 1991;259(2):566-73
87. Adeniyi AF, Adeleye JO, Adeniyi CY. Diabetes, sexual dysfunction and therapeutic exercise: a 20 year review. Curr Diabetes Rev 2010;6(4):201-6
88. Esposito K, Maiorino MI, Bellastella G, et al. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res 2010;22(3):179-84